What does microsatellite instability (MSI) mean for Prostate Cancer

Understanding Microsatellite Instability (MSI) in Prostate Cancer

What MSI Actually Is

Microsatellite instability refers to errors in your DNA that aren't being corrected. Here's a helpful way to think about it:

The Typewriter Analogy: Imagine your DNA is like typing on a typewriter. Normally, when you make mistakes while typing, a spell-checker catches and fixes them. With MSI, those errors occur during DNA replication, but your body's "spell-checker" (called mismatch repair, or dMMR) isn't working properly. So errors accumulate and don't get fixed. The result is that your tumor cells have a much higher number of mutations than typical prostate cancer cells.

How Common Is MSI in Prostate Cancer?

According to the NCCN Guidelines for Prostate Cancer, MSI-high (MSI-H) is relatively rare in prostate cancer—occurring in only 3-5% of cases. This is important because it means if you have MSI-H, you're in a small but potentially significant group.

Why MSI Matters for Treatment

The Clinical Reasoning: Doctors care about MSI because of how it affects your immune system's ability to fight cancer. When tumor cells have many mutations (like with MSI-H), those mutations act like "red flags" that signal to your immune system: "These cells are abnormal—attack them!" This makes MSI-H tumors potentially more responsive to immunotherapy.

MSI and Immunotherapy Response

What the Evidence Shows:

According to research presented in the CancerPatientLab webinar "How MSI and Other Tests Can Guide Immunotherapies for Cancer Treatment" by Heather Tomlinson:

• MSI-H was the first tissue-agnostic biomarker approved by the FDA (in 2017), meaning it's approved for treatment decisions regardless of cancer type
• For prostate cancer patients with MSI-H who have already received docetaxel (chemotherapy) and a novel hormone therapy, Keytruda (pembrolizumab) is FDA-approved as a subsequent treatment option
• However, prostate cancer is what experts call a "cold tumor" with relatively few mutations overall, which is why immunotherapies are generally less effective in prostate cancer compared to other cancers

Important Reality Check: Dr. [removed] Subudhi, a leading prostate cancer immunotherapy specialist, notes that while MSI-H shows promise, the results in prostate cancer are more modest than in other cancers. In his research, patients with MSI-H prostate cancer treated with anti-PD-1 therapy (like Keytruda) showed:

• A 50% response rate (meaning half of patients saw some benefit)
• A 25% durable response rate (meaning only about 1 in 4 patients had lasting responses)

This is very different from colorectal cancer with MSI-H, where response rates are much higher.

What Testing Involves

According to NCCN Guidelines, tumor testing for MSI or mismatch repair deficiency is:

• Recommended for patients with metastatic prostate cancer
• May be considered for patients with regional or castration-sensitive metastatic prostate cancer

The testing can be done on:

• A tissue biopsy from your tumor
• Circulating tumor DNA (ctDNA) from a blood test, though this is less reliable when PSA is undetectable

Important Genetic Counseling Consideration

If you're found to have MSI-H, genetic counseling is recommended. Here's why: MSI-H can sometimes be associated with hereditary cancer syndromes (like Lynch syndrome), though not all MSI-H tumors are hereditary. A genetic counselor can help determine if your MSI-H finding has implications for your family members.

Questions to Ask Your Oncologist

If you're considering MSI testing or have been found to have MSI-H:

1. "Should I have MSI testing done, and if so, what type of test do you recommend?"
2. "If I have MSI-H, am I a candidate for Keytruda or other immunotherapies?"
3. "What other treatments should I consider alongside or instead of immunotherapy?"
4. "Should I be referred to genetic counseling to understand if this has implications for my family?"
5. "Are there clinical trials available for MSI-H prostate cancer patients?"

The Bottom Line

MSI-H in prostate cancer is uncommon but potentially meaningful. It may open the door to immunotherapy options that wouldn't otherwise be available. However, prostate cancer's "cold tumor" nature means that even with MSI-H, immunotherapy responses tend to be more modest than in other cancer types. Your oncologist will need to evaluate your complete clinical picture—including your prior treatments, overall health, and other biomarkers—to determine if MSI-H testing and immunotherapy are right for you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.